Similarly, inactivating point mutations of tumor suppressors TP53 and PTEN were identified in exoDNA from prostate cancer cell lines bearing these mutations (Lázaro-Ibáñez et al., 2014). This evidence concerns the gene TP53 and prostate cancer.